Abstract
Autoimmune diseases, owing to their chronic onset and immune imbalance, seriously affect the quality of life of patients. Existing treatment methods have limited efficacy and significant side effects. Chimeric antigen receptor (CAR)-based cell therapy strategies, particularly CAR-T cell therapy, are emerging as a promising approach for treating autoimmune diseases. Therefore, this study systematically evaluated the application progress, safety, and target selection of CAR-T therapy in autoimmune diseases and clarified its clinical potential. Through a systematic review and analysis of clinical trial data on CAR-T cell therapy for autoimmune diseases worldwide, combined with target types, research stages, and trial status, a systematic analysis was conducted to explore the efficacy and safety of different targets and summarize the results of existing research. Early-stage studies account for the vast majority of relevant trials registered globally. CD19-targeting CAR-T cells have exhibited significant therapeutic effects in various autoimmune diseases, especially in difficult-to-treat cases. The research on new targets such as B cell maturation antigen and CD20 has also made positive progress. CAR-T cell therapy provides a potential new treatment option for autoimmune diseases, and the trend of diversified targets provides a new path for precision treatment, warranting further in-depth research and clinical translation.
Keywords: autoimmune diseases, CAR-T cell therapy, clinical trials, immunotherapy, targets
1. Introduction
Autoimmune diseases are a group of chronic conditions characterized by abnormalities in the immune system, with common types including systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), and multiple sclerosis. These diseases typically present as chronic and recurrent, often involving multiple organs. In recent years, the global prevalence of autoimmune diseases has risen, increasing the burden on healthcare systems and economies and profoundly impacting the lives of patients. Specifically, patients often experience high rates of disability due to immune imbalance and impaired immune tolerance, resulting in a significant decline in quality of life.[1] Notably, these conditions often require lifelong management, and many patients experience fluctuating disease activity. While traditional treatments can alleviate clinical symptoms to some extent, their efficacy remains limited, and their long-term use is often associated with significant side effects such as drug resistance, disease recurrence, infection, and increased risk of tumors associated with systemic immunosuppression.[2] The lack of curative therapies leaves patients vulnerable to repeated disease flares and cumulative organ damage over time. Therefore, more precise and targeted treatment strategies are urgently needed to effectively control disease activity, restore immune tolerance, and improve long-term patient outcomes.
Chimeric antigen receptor (CAR)-based cell therapy strategies, such as CAR-T cell therapy, are emerging as a new approach for treating autoimmune diseases owing to their precision and controllability, with encouraging therapeutic effects and prospects in patients with refractory autoimmune diseases.[3] CAR-T technology, initially developed for hematological malignancies, is now being actively explored in the field of autoimmunity, supported by preclinical models and early clinical evidence. CAR-T cell structure includes extracellular antigen-recognition, transmembrane, and intracellular signal transduction domains. They typically use single-chain variable fragments to recognize target antigens and enhance T cell activation, proliferation, and effector functions through the intracellular CD3ζ signaling domain as well as co-stimulatory domains such as CD28 or 4-1BB.[4] This design allows for flexible targeting of disease-relevant cell populations, such as autoreactive B cells or plasma cells, which are central drivers in many autoimmune processes.[5] Compared to traditional antibody therapies, CAR-T cell therapy can effectively eliminate pathogenic B and plasma cells circulating in the bloodstream and residing in tissues. Their long-term persistence in the body enables continuous immune status monitoring, promoting immune homeostasis restoration and sustained remission.[6] Additionally, CAR-T cell therapy holds the potential to reestablish immune tolerance and induce durable, drug-free remission, representing a paradigm shift from chronic suppression to immune modulation.
A crucial determinant of the clinical success of CAR-T cell therapy for autoimmune diseases lies in the selection of appropriate therapeutic targets. At present, most studies have focused on B cell-related antigens such as CD19, CD20, and B cell maturation antigen (BCMA), reflecting the pivotal role of B cells and plasma cells in disease pathogenesis. Novel targets are under exploration, expanding the therapeutic landscape of CAR-T cell applications in autoimmunity.[7]
In this review, we systematically summarized the progress of CAR-T therapy for autoimmune diseases, using the Informa database, with a particular focus on the selection and evaluation of therapeutic targets. By comprehensively analyzing the range of molecular and cellular targets that have been explored, we provided an in-depth overview of the mechanistic rationale and therapeutic relevance of each target in various autoimmune conditions. We integrated clinical trial results, published studies, and preclinical research as supporting evidence to assess the efficacy and safety of targeting these molecules. Additionally, we discussed current trends, unresolved challenges, and future directions for target selection in CAR-T cell therapy for autoimmunity. Our aim was to offer both theoretical support and practical reference for the clinical treatment and optimization of CAR-T cell strategies. Ultimately, our findings are expected to guide future development of more precise and effective CAR-T therapies for complex autoimmune diseases.
2. Methods
2.1. Ethical approval
This study does not involve human participants, clinical data, experimental animals, or histological research. All analyzed data comes from publicly available video databases, and data collection fully complies with the terms of service. No personal or personally identifiable information has been collected or processed, nor has there been any interaction with the user. Therefore, moral approval is not required.
2.2. Search strategy and screening criteria
To systematically examine the current landscape of CAR-T cell therapies in the treatment of autoimmune diseases, we conducted a comprehensive analysis of global clinical trials retrieved from the Informa database. This database aggregates information from over 40,000 public sources, including ClinicalTrials.gov and the Global Gene Therapy Clinical Trials Database. All relevant trials registered from the inception of the database up to July 31, 2025, were included in the analysis. Eligible studies were those investigating CAR-T cell therapies as the primary drug type for autoimmune or inflammatory diseases. These parameters ensured that only trials directly involving CAR-T therapy in autoimmune or inflammatory disease contexts were selected for evaluation. To enhance methodological rigor, we applied clear inclusion and exclusion criteria. Eligible studies met all of the following criteria: investigation of CAR-T cell mechanisms in autoimmune diseases, identification of specific therapeutic targets or mechanisms of action, and design as clinical trials. We excluded studies that did not define therapeutic mechanisms or targets, lacked sufficient or complete data, or were non-interventional in nature (such as observational studies) (Fig. 1). During the initial extraction phase, we mapped clinical trials from multiple registries. To ensure the accuracy of categorical variables such as trial phase and status, we performed a manual cross-checking process across ClinicalTrials.gov, the Chinese Clinical Trial Registry, and the EU Clinical Trials Register. Upon noting discrepancies such as differences in trial status or missing phase information, we prioritized the most recently updated entry, and in some cases, referred to sponsor websites or publications for verification. To enhance the consistency of data extraction, 2 reviewers independently extracted trial attributes using a prespecified coding framework. Disagreements were resolved through consensus, and inter-rater reliability was periodically assessed. For multisource trials, we conducted cross-validation by comparing trial identifiers, such as NCT numbers and key metadata, to confirm alignment across datasets.
Figure 1.
Studying selection process of CAR-T cell therapies in the treatment of autoimmune diseases. CAR = chimeric antigen receptor.
To minimize potential bias during the screening process, 2 reviewers independently applied the eligibility criteria to all identified studies. Discrepancies between reviewers were resolved through discussion and consensus. If consensus could not be reached, a third senior reviewer was consulted to make the final decision. For studies with partially missing datasets, such as absent or unclearly defined therapeutic endpoints or mechanistic pathways, we did not employ data imputation owing to the qualitative nature of our synthesis. Instead, we applied triangulation using secondary sources, including clinical trial registries, peer-reviewed protocols, and regulatory filings, to retrieve missing information.
For trials with vaguely described therapeutic goals, further assessment was carried out using independent sources or databases to determine their eligibility. If sufficient information to confirm the therapeutic intent could not be obtained, the study was excluded from the final analysis. A rigorous strategy was also implemented to identify and address data gaps, thereby strengthening the credibility of the review. Studies that did not report essential outcome information, particularly those lacking clearly defined primary or secondary endpoints, were not considered. Emphasis was placed on selecting studies with explicit therapeutic objectives and comprehensive datasets to enhance data integrity and support more robust and reliable comparisons.
2.3. Statistical analysis
Statistical analysis was conducted using SPSS Statistics version 22.0 (IBM Corp., Armonk). Categorical data were summarized in terms of frequencies and proportions. A comprehensive 10-year evaluation was carried out to assess trends in core indicators, including the annual volume of clinical trials, phase-wise classification, geographic distribution by nation, therapeutic categories, mechanisms of action, and molecular targets. The start date of each study was used to assign its corresponding year. Recognizing the diversity in patient populations, therapeutic targets, and trial objectives, we conducted exploratory subgroup analyses to examine whether notable trends emerged across key strata. Specifically, we compared trials targeting CD19 versus BCMA antigens and noted differences in trial phase distribution and geographic patterns. Additionally, we compared early-phase (Phase I/II) and late-phase (Phase III/IV) studies to explore potential differences in sponsor type, recruitment status, and registration timing. Although descriptive in nature, these sensitivity explorations provide contextual insights and support the robustness of our overall findings.
3. Results
3.1. Clinical trial phases and status
This study systematically reviewed and analyzed the distribution and characteristics of clinical trials of CAR-T cell therapy for autoimmune diseases worldwide from database establishment to 2025. Manual screening identified 119 registered clinical trials. Given the study and non-meta-analytic nature of this review, we did not conduct a formal statistical power calculation. Nevertheless, the inclusion of 119 trials reflects a comprehensive collection of all eligible studies registered to date. Therefore, the sample size is considered sufficient to support robust descriptive conclusions and characterize the current landscape of CAR-T research in autoimmune diseases.
Analysis of both trial phases and statuses revealed a consistent pattern indicating that CAR-T cell therapy for autoimmune diseases remains in its early stages of clinical development. Of the 119 registered trials, 70 were in Phase I, 30 in Phase I/II, and 15 in Phase II, collectively representing the majority of ongoing efforts focused on safety, tolerability, and preliminary efficacy. Only one trial has progressed to Phase III and three advanced to Phase IV, suggesting that transition into late-stage clinical evaluation remains limited (Fig. 2). This observation is further supported by the trial status: most studies are either actively recruiting or categorized as planned (25.21%), whereas only 9.24% are marked as completed. A few trials have been terminated or closed, potentially owing to design limitations or recruitment challenges. Together, these data highlight the nascent and dynamic state of CAR-T cell therapy research in autoimmune diseases, reflecting both early momentum and substantial opportunities for clinical advancement (Fig. 3).
Figure 2.
Trial phase of CAR-T cell therapies in the treatment of autoimmune diseases. CAR = chimeric antigen receptor.
Figure 3.
Trial status of CAR-T cell therapies in the treatment of autoimmune diseases. CAR = chimeric antigen receptor.
3.2. Target distribution
From the perspective of target distribution, the current global research focuses on CAR-T cell therapy for autoimmune diseases centers around several key molecular targets. Among these, CD19 has been the most extensively investigated, with 97 related studies, reflecting its pivotal role in depleting pathogenic B cells across multiple autoimmune conditions. BCMA, which targets long-lived plasma cells, ranks second with 31 studies, highlighting its growing relevance in diseases involving autoreactive antibody production.
Other targets under active investigation include CD20, B cell activating factor (BAFF), and interleukin 1 receptor type 1, each representing alternative immune regulatory pathways beyond conventional B cell targeting. In addition, a number of early-stage studies have begun to explore less conventional targets such as TACI, RRM1, RRM2, FLT3, and CD33, suggesting a shift toward a more diversified targeting strategy (Fig. 4).
Figure 4.
Targets of CAR-T cell therapies in the treatment of autoimmune diseases. CAR = chimeric antigen receptor.
4. Discussion
A comprehensive analysis of the current landscape of clinical trials investigating CAR-T cell therapy for autoimmune diseases reveals that this field remains in its early stages of development, both in terms of trial phase and operational status. The present systematic review of registered studies up to 2025 identified a total of 119 clinical trials. Notably, the joint distribution of trial phase and trial status reveals a highly active but immature research landscape. The fact that most studies are both in early phases and remain either open or planned indicates that CAR-T therapy in autoimmune diseases remains in a foundational exploratory phase, with the overall translational pipeline far from maturity. Core issues such as optimal dosing, target specificity, and safety management protocols are likely still under development, and the therapeutic paradigm remains unstandardized across indications.
Further insights into the progression of these trials can be gained by analyzing their operational status. The limited proportion of completed trials and the extremely small number that have progressed to Phase III or IV reflect a lack of conclusive clinical evidence to date. This scarcity of endpoint-driven results contributes to uncertainty regarding the long-term efficacy, relapse risk, and cost-effectiveness of CAR-T therapy in autoimmune diseases. The small number of terminated or closed trials may reflect challenges in trial execution, including patient recruitment, manufacturing complexity, or adverse outcomes, further emphasizing the fragility of the current development landscape. Many studies are currently open and actively recruiting or treating participants, while an additional 25.2% are marked as planned, suggesting to robust and expanding pipeline of upcoming research. In contrast, only 9.2% of the trials have been completed, indicating that few studies have the far reached a stage where final data can inform practice or policy.
Taken together, the combined analysis of trial phase and status underscores the early and dynamic nature of CAR-T therapy in autoimmune diseases. The predominance of early-phase and ongoing trials suggests that the field is still building its foundational evidence base. At the same time, the strong presence of planned studies reflects sustained research interest and therapeutic optimism. Consequently, this area offers significant opportunities for future clinical advancement, mechanistic exploration, and eventual therapeutic breakthrough.
4.1. CD19-targeted therapy
We also analyzed the targets of CAR-T therapy in autoimmune diseases. B cells play a central role in the occurrence and progression of various autoimmune diseases. Moreover, their pathological mechanisms involve not only antibody-mediated immune responses but also antigen presentation, cytokine secretion, and T cell activation. Treatment strategies targeting B cells have become an important direction for intervention in autoimmune diseases in recent years. Among them, CD19 has been selected as a CAR-T cell therapeutic target owing to its high specificity to the B cell lineage and its expression throughout B cell differentiation.[8] By targeting CD19, CAR-T cells can effectively eliminate mature B cells and their precursors, inhibiting autoantibody production and enabling disease remission or even long-term disease control. An animal study used viral transduction to prepare CD19-targeted CAR-T cells in 2 SLE mouse models, with the modified cells then administered via a single infusion into diseased mice to systematically evaluate their therapeutic efficacy. The results revealed that the CAR-T cells could completely eliminate CD19+ B cells in vivo over the long term, significantly reduce serum autoantibody levels, and effectively alleviate pathological damage to organs such as the kidneys and skin. Additionally, CAR-T therapy significantly prolonged the survival of mice, with efficacy lasting for over a year. Further studies demonstrated that CAR-T cells can also regulate T cell subsets, reduce levels of inflammation-related proteins, and demonstrate good safety in vivo.[9] Another animal experiment demonstrated that a single infusion of anti-CD19 CAR-T cells in an SLE mouse model can effectively and sustainably deplete peripheral B cells, delay the progression of lupus nephritis and skin lesions, and significantly prolong survival.[10] Both animal experiments confirmed the therapeutic potential of CD19-targeted CAR-T cells in SLE mouse models; however, their efficacy and mechanisms of action require further refinement and exploration.
Similarly, clinical studies have demonstrated that CAR-T cell therapy targeting CD19 can rapidly and persistently eliminate pathogenic B cells, thereby alleviating the clinical symptoms of patients. For example, in a refractory patient with both myasthenia gravis and RA, after receiving CD19 CAR-T cell therapy, a comprehensive assessment using clinical scoring, antibody testing, and immunological follow-up revealed that peripheral blood B cells were continuously eliminated, and symptoms of both myasthenia gravis and RA improved significantly and achieved complete remission. Further testing revealed seroconversion of RA-associated antibodies to negative, a significant decrease in antinuclear antibody titer, and that the treatment was well tolerated. These results indicate that CD19 CAR-T cells extensively eliminate pathogenic B cells and induce seroconversion of certain autoantibodies, offering new treatment hope for patients with refractory autoimmune diseases and suggesting potential heterogeneity among different autoantibody mechanisms.[11] Another study evaluated lymphoid tissue B cell clearance and structural changes in inguinal lymph node biopsy samples from 24 patients with autoimmune diseases before and after treatment with different B cell depletion strategies. The results indicated that CD19 CAR-T cells completely eliminated B cells in lymph nodes in all cases and disrupted the follicular structure. In contrast, protein-based B cell depletion agents reduced peripheral and lymph node B cells but failed to achieve complete depletion, with follicular structure largely preserved. While CAR-T therapy can achieve stable drug-free remission, incomplete clearance may lead to disease recurrence.[12] A prospective cohort study found that CAR-T therapy-associated local immune effector cell toxicity syndrome is relatively common, manifesting as mild to moderate self-limiting inflammatory reactions in affected organs posttreatment; however, most patients do not require special intervention and have good outcomes.[13] Thus, CD19-targeted CAR-T cell therapy can provide significant relief for various refractory autoimmune diseases.
4.2. Emerging targets
With the continuous advancement of CAR-T cell technology, other surface antigens on B cells, such as CD20, CD22, CD70, and CD33, are also being gradually developed as new therapeutic targets. CD20 is a transmembrane protein expressed predominantly on mature B lymphocytes but is absent from hematopoietic stem cells and plasma cells. Notably, CD20 is widely expressed in most B cell malignancies and is also present on autoreactive B cells, which are implicated in various autoimmune diseases. By genetically engineering autologous T cells to express CARs targeting CD20, these modified T cells can selectively recognize and eliminate all CD20-positive B cells, including both malignant and autoreactive populations. Early clinical studies of CD20-targeted CAR-T cell therapy in autoimmune diseases have yielded encouraging results.[14] Owing to their specific expression in certain B cell subsets, plasma cells, or related pathological states, molecules such as CD70 and CD33 offer additional options for addressing CD19-negative or relapsed patients. In-depth research into these targets holds promise for further refining B cell-targeted CAR-T strategies, enhancing their broad applicability and personalized precision in the treatment of autoimmune diseases.
BAFF and its associated receptors collectively form a critical signaling axis that regulates B cell survival, maturation, and antibody production. Dysregulation of the BAFF pathway is a key feature of various autoimmune diseases, leading to abnormal proliferation and the persistent presence of self-reactive B cells and pathogenic plasma cells. In recent years, multiple clinical trials have demonstrated that CAR-T cell therapy targeting BAFF and its associated receptors is effective in treating autoimmune diseases.[15]
As a key member of the tumor necrosis factor ligand superfamily, BAFF plays a pivotal role in B cell maturation, survival, and differentiation by engaging with its specific receptors. Aberrant activation of BAFF and its downstream signaling pathways has been closely linked to the pathogenesis of autoimmune diseases such as SLE.[16] Building on this mechanistic insight, traditional therapeutic approaches that block BAFF or its receptors have demonstrated efficacy in ameliorating SLE symptoms, thereby providing a strong rationale for the development of CAR-T cell therapies targeting BAFF. Recent research has advanced this concept by developing BAFF ligand-based CAR-T cells, which can also target BCMA. These cells were evaluated using both in vitro co-culture cytotoxicity assays with peripheral blood mononuclear cells from SLE patients and in vivo models, including humanized and mouse lupus models. The findings revealed that BAFF CAR-T cells efficiently depleted autoreactive B cells and long-lived plasma cells, resulting in a significant reduction in autoantibody levels, improved proteinuria, and prolonged survival. Notably, BAFF CAR-T cells outperformed conventional CD19 CAR-T cells in eliminating CD138 + plasma cells, thus addressing a major therapeutic gap in refractory SLE by specifically targeting persistent antibody-secreting cells.[17]
In parallel, BCMA has emerged as another promising target for CAR-T cell therapy. BCMA is predominantly expressed on the surface of plasma cells and some memory B cells, with minimal or undetectable expression in other healthy tissues, conferring high tissue specificity. This restricted expression pattern renders BCMA an attractive candidate for targeted therapies, especially in autoimmune diseases.[18] Physiologically, BCMA interacts with its ligands BAFF and APRIL to maintain the survival, proliferation, and differentiation of B cells, particularly plasma cells. However, under pathological conditions such as autoimmunity, the persistent activation and expansion of BCMA-positive plasma cells lead to the continuous production of pathogenic autoantibodies, which directly drive autoimmune tissue damage. By engineering CAR-T cells to specifically recognize and eliminate these BCMA-expressing pathological plasma cells, it is possible to achieve a marked reduction in autoantibody titers and amelioration of disease symptoms. Furthermore, the depletion of these cells suppresses the original pool of self-reactive B cells, thereby facilitating immune reconstitution and enabling the reemergence of nonself-reactive B cell populations, which is essential for restoring immune tolerance.[19] Lupus nephritis is a severe manifestation of SLE. A clinical trial enrolled seven patients with biopsy-confirmed refractory lupus nephritis, who received personalized anti-BCMA CAR-T cells following lymphodepleting chemotherapy. This therapeutic approach effectively induced and maintained disease remission in most patients. Multiple kidney biopsies revealed a significant reduction in immune complex deposition, and the pro-inflammatory state of peripheral lymphocytes was also alleviated, with no serious adverse events observed.[20] Additionally, preliminary evidence has emerged regarding the application of BCMA as a target in other autoimmune diseases. For example, a case report described the use of teclistamab, a bispecific T cell engager antibody that simultaneously targets BCMA and CD3, in a patient with severe, refractory myasthenia gravis who tested positive for anti-LRP4 antibodies. Despite the patient having previously failed multiple standard and experimental immunosuppressive therapies, teclistamab led to rapid and sustained disease remission, with residual circulating B cells cleared, pathogenic autoantibodies eliminated, and significant functional recovery.[21]
4.3. Safety considerations
CAR-T cell therapy provides a potential new treatment option for autoimmune diseases. Targets such as CD19, BCMA, and CD20 offer clear advantages in inducing disease remission, with long-lasting efficacy and good safety. At the same time, target selection is exhibiting a diversified trend, laying the foundation for personalized treatment. However, this field is still in the early stages of clinical exploration, with most studies focused on Phase I/II and lacking long-term follow-up data and standardized treatment plans. The present review is limited by its reliance on publicly available clinical trial data, which may exclude unpublished or ongoing early-stage research. Most current evidence is largely based on small-scale or early-phase studies, and long-term outcomes remain uncertain. Additionally, heterogeneity in study design and patient populations complicates direct comparisons. Larger, long-term clinical trials are needed to validate these findings. Therefore, the findings must be carefully interpreted, considering potential publication and registration biases. Specifically, trials with positive or statistically significant results are more likely to be registered and published, potentially leading to an overrepresentation of favorable outcomes in the data. Conversely, terminated or negative-result trials may be underreported or subject to delays in posting, thereby limiting transparency. These biases can skew the perceived evidence landscape and should be acknowledged when interpreting the distribution and characteristics of registered studies. Furthermore, considerable heterogeneity exists in trial design across registries, and differences in geographic location, population demographics, and endpoint definitions can significantly affect the comparability of studies. For example, trials conducted in high-income versus low- and middle-income countries may differ in inclusion criteria, access to standard care, and outcome relevance. Therefore, recognizing this heterogeneity is crucial for contextualizing the results and for avoiding overgeneralization when comparing trials across settings. Future research should focus on CAR-T structural optimization, efficacy validation, and safety management, promoting its standardized application and mechanism exploration in more autoimmune diseases.
5. Conclusion
In summary, CAR-T cell therapy has demonstrated promising efficacy and safety in the treatment of refractory autoimmune diseases, with CD19, BCMA, and CD20 as primary targets. The ongoing exploration of new antigens expands treatment possibilities and reflects progress toward more personalized therapies. However, challenges remain, including immune-related toxicity, limited long-term follow-up, and the risk of antigen escape. Future research should focus on optimizing CAR-T cell design, expanding the clinical evidence base, and addressing safety concerns to further improve therapeutic outcomes for diverse subtypes of autoimmune diseases.
Acknowledgments
We thank all databases for their contribution to this study.
Author contributions
Conceptualization: Tong Wang, Ying Tong.
Data curation: Ying Tong.
Methodology: Ying Tong.
Supervision: Ying Tong.
Visualization: Tong Fu.
Writing – original draft: Ying Tong.
Writing – review & editing: Tong Wang, Tong Fu, Guoli Xing, Hongbo Cai, Ying Tong.
Abbreviations:
- BAFF
- B cell activating factor
- BCMA
- B cell maturation antigen
- CAR
- chimeric antigen receptor
- RA
- rheumatoid arthritis
- SLE
- systemic lupus erythematosus
This work was supported by the “Double First-class” Integrated Traditional Chinese and Western Medicine Discipline Development Fund under Grant [No. 15041180133].
The authors have no conflicts of interest to disclose.
The datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request.
How to cite this article: Wang T, Fu T, Xing G, Cai H, Tong Y. Advances and prospects of CAR-T cell therapy in autoimmune disease treatment. Medicine 2025;104:47(e45698).
Contributor Information
Tong Wang, Email: ceciliaki1698@brandeis.edu.
Tong Fu, Email: ceciliaki1698@brandeis.edu.
Guoli Xing, Email: xingguoli@hljucm.edu.cn.
Hongbo Cai, Email: caihongbo@hljucm.edu.cn.
References
- [1].Liu J, Zhao Y, Zhao H. Chimeric antigen receptor T-cell therapy in autoimmune diseases. Front Immunol. 2024;15:1492552. [DOI] [PMC free article] [PubMed] [Google Scholar]
- [2].Zeng Z, Mao H, Lei Q, He Y. IL-7 in autoimmune diseases: mechanisms and therapeutic potential. Front Immunol. 2025;16:1545760. [DOI] [PMC free article] [PubMed] [Google Scholar]
- [3].Wang M. Repurposing CAR T cells to treat SLE. Nat Rev Nephrol. 2019;15:319. [DOI] [PubMed] [Google Scholar]
- [4].Wen R, Li B, Wu F, et al. Chimeric antigen receptor cell therapy: a revolutionary approach transforming cancer treatment to autoimmune disease therapy. Autoimmun Rev. 2025;24:103859. [DOI] [PubMed] [Google Scholar]
- [5].Javan MR, Akhlaghi M, Hormozi A, Hosseini M, Khosrojerdi A. Mast cells in autoimmune disease: unveiling their multifaceted roles and therapeutic potential. Hum Immunol. 2025;86:111334. [DOI] [PubMed] [Google Scholar]
- [6].Nie W, Yang X, Ma M, Xu X, Hou J. Chimeric antigen receptor T cell therapy for autoimmune diseases. Curr Opin Immunol. 2025;95:102596. [DOI] [PubMed] [Google Scholar]
- [7].Felten R, Mertz P, Sebbag E, Scherlinger M, Arnaud L. Novel therapeutic strategies for autoimmune and inflammatory rheumatic diseases. Drug Discov Today. 2023;28:103612. [DOI] [PubMed] [Google Scholar]
- [8].Forsthuber TG, Cimbora DM, Ratchford JN, Katz E, Stüve O. B cell-based therapies in CNS autoimmunity: differentiating CD19 and CD20 as therapeutic targets. Ther Adv Neurol Disord. 2018;11:1756286418761697. [DOI] [PMC free article] [PubMed] [Google Scholar]
- [9].Jin X, Xu Q, Pu C, et al. Therapeutic efficacy of anti-CD19 CAR-T cells in a mouse model of systemic lupus erythematosus. Cell Mol Immunol. 2021;18:1896–903. [DOI] [PMC free article] [PubMed] [Google Scholar]
- [10].Kansal R, Richardson N, Neeli I, et al. Sustained B cell depletion by CD19-targeted CAR T cells is a highly effective treatment for murine lupus. Sci Transl Med. 2019;11:eaav1648. [DOI] [PMC free article] [PubMed] [Google Scholar]
- [11].Haghikia A, Hegelmaier T, Wolleschak D, et al. Clinical efficacy and autoantibody seroconversion with CD19-CAR T cell therapy in a patient with rheumatoid arthritis and coexisting myasthenia gravis. Ann Rheum Dis. 2024;83:1597–8. [DOI] [PubMed] [Google Scholar]
- [12].Tur C, Eckstein M, Bucci L, et al. Effects of different B-cell-depleting strategies on the lymphatic tissue [published online ahead of print July 11, 2025]. Ann Rheum Dis. doi: 10.1016/j.ard.2025.06.2120. [DOI] [PubMed] [Google Scholar]
- [13].Hagen M, Müller F, Wirsching A, et al. Local immune effector cell-associated toxicity syndrome in CAR T-cell treated patients with autoimmune disease: an observational study. Lancet Rheumatol. 2025;7:e424–33. [DOI] [PubMed] [Google Scholar]
- [14].Wang M, DeStefano VM, Ding L, et al. Validation of BCMA-CD19 compound CAR-T therapy in SLE overlap syndrome: over 1.5-year follow-up. Stem Cell Rev Rep. 2025;21:1750–9. [DOI] [PubMed] [Google Scholar]
- [15].Zhou J, Lei B, Shi F, et al. CAR T-cell therapy for systemic lupus erythematosus: current status and future perspectives. Front Immunol. 2024;15:1476859. [DOI] [PMC free article] [PubMed] [Google Scholar]
- [16].Stohl W. Inhibition of B cell activating factor (BAFF) in the management of systemic lupus erythematosus (SLE). Expert Rev Clin Immunol. 2017;13:623–33. [DOI] [PubMed] [Google Scholar]
- [17].Uppin V, Gibbons H, Troje M, et al. CAR-T cell targeting three receptors on autoreactive B cells for systemic lupus erythematosus therapy. J Autoimmun. 2025;151:103369. [DOI] [PubMed] [Google Scholar]
- [18].Schett G, Mackensen A, Mougiakakos D. CAR T-cell therapy in autoimmune diseases. Lancet. 2023;402:2034–44. [DOI] [PubMed] [Google Scholar]
- [19].Hernández-López A, Olaya-Vargas A, Bustamante-Ogando JC, Meneses-Acosta A. Expanding the horizons of CAR-T cell therapy: a review of therapeutic targets across diverse diseases. Pharmaceuticals (Basel). 2025;18:156. [DOI] [PMC free article] [PubMed] [Google Scholar]
- [20].Hu Z, Cai S, Yu Y, et al. BCMA-targeted CAR T cell therapy can effectively induce disease remission in refractory lupus nephritis. Ann Rheum Dis. 2025;84:1675–83. [DOI] [PubMed] [Google Scholar]
- [21].Schreiber S, Al-Dubai M, Vielhaber S, et al. Effective use of BCMA-targeting bispecific T cell-engaging antibody in treatment-refractory LRP4+ myasthenia gravis. Mol Ther. 2025;33:4130–4. [DOI] [PMC free article] [PubMed] [Google Scholar]




